Investor Presentaiton

DNA Positive development in full year financial KPI's EUR, million Net sales Q4/2018* 236.9 Q4/2018 adjusted 237.5 Q4/2017 Change % 1-12/2018* 234.6 1.2% 911.8 1-12/2018 adjusted 913.5 1-12/2017 Change % 886.1 3.1% Comparable EBITDA 65.4 62.7 65.7 -4.5% 284.9 283.6 271.8 4.4% % of Net Sales 27.6% 26.4% 28.0% 31.2% 31.0% 30.7% Comparable Operating Result 28.4 25.1 29.9 -16.1% 138.9 133.8 126.6 5.7% % of Net Sales 12.0% 10.6% 12.8% 15.2% 14.6% 14.3% Net Result 21.2 18.5 21.6 -14.1% 102.2 98.1 93.1 5.4% % of Net Sales 8.9% 7.8% 9.2% 11.2% 10.7% 10.5% Operative Capex 53.7 53.8 67.3 -20.1% 133.9 134.7 132.9 1.3% % of Net Sales 22.7% 22.7% 28.7% 14.7% 14.7% 15.0% Operating FCF 11.7 8.9 -1.7 151.0 149.0 138.9 7.3% Net Debt 379.3 379.3 304.3 1.33 1.34 1.12 Net Debt/EBITDA Notes 1. Operating free cash flow defined as comparable EBITDA minus operative capex Figures adjusted are disclosed as if they were prepared under 2017 revenue guidance, excluding the impact of IFRS 15 standard adopted on 1 January 2018. *Including IFRS 15 DNA's Investor presentation, February 2019 25

View entire presentation